Another drug is CT327/SNA-120, a topical TRPV1 pathway inhibitor (Figure 4b) that demonstrated its safety and efficacy in a phase IIb clinical trial for psoriasis [160]. The gene discussed is TRPV1; the disease is psoriasis.